NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free CSTL Stock Alerts $19.20 +0.36 (+1.91%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$18.50▼$19.3850-Day Range$18.06▼$25.3052-Week Range$9.26▼$26.70Volume139,713 shsAverage Volume237,002 shsMarket Capitalization$527.04 millionP/E RatioN/ADividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Castle Biosciences alerts: Email Address Castle Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.5% Upside$31.00 Price TargetShort InterestBearish5.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 6 Articles This WeekInsider TradingSelling Shares$1.05 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.41) to ($2.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector591st out of 918 stocksMedical Laboratories Industry14th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCastle Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.21% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Castle Biosciences has recently increased by 0.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 2.6 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Castle Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,051,065.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to grow in the coming year, from ($2.41) to ($2.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -8.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -8.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Castle Biosciences Stock (NASDAQ:CSTL)Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More CSTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSTL Stock News HeadlinesApril 18, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,947 Shares of StockApril 11, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 2,400 SharesApril 18, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 9, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 9,152 SharesApril 6, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,368 Shares of StockMarch 24, 2024 | insidertrades.comDerek J. Maetzold Sells 2,295 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockApril 18, 2024 | investing.comCastle Biosciences CEO sells over $100k in company stockApril 17, 2024 | finance.yahoo.comWe're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash BurnApril 18, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 12, 2024 | americanbankingnews.comDaniel Bradbury Sells 2,400 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockApril 11, 2024 | businesswire.comCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024April 10, 2024 | finance.yahoo.comCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsApril 10, 2024 | businesswire.comCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsApril 10, 2024 | finance.yahoo.comCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearApril 10, 2024 | businesswire.comCastle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearApril 10, 2024 | investing.comCastle Biosciences director sells over $440k in company stockApril 5, 2024 | finance.yahoo.comWhat Makes Castle Bioscience (CSTL) a Prospective Investment?April 4, 2024 | finance.yahoo.comPresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerApril 4, 2024 | businesswire.comPresentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerMarch 27, 2024 | businesswire.comCastle Biosciences Announces Updates to its Board of DirectorsMarch 25, 2024 | finance.yahoo.comCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearMarch 22, 2024 | businesswire.comLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBMarch 20, 2024 | finance.yahoo.comDoes Castle Bioscience (CSTL) Have Robust Growth Prospects?March 19, 2024 | businesswire.comLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyMarch 16, 2024 | finance.yahoo.comCSTL Apr 2024 17.500 callMarch 15, 2024 | finance.yahoo.comNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderMarch 15, 2024 | businesswire.comNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderSee More Headlines Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/18/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees610Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$37.00 Low Stock Price Target$25.00 Potential Upside/Downside+61.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,470,000.00 Net Margins-26.15% Pretax Margin-26.10% Return on Equity-14.92% Return on Assets-13.20% Debt Debt-to-Equity RatioN/A Current Ratio6.20 Quick Ratio6.04 Sales & Book Value Annual Sales$219.79 million Price / Sales2.41 Cash FlowN/A Price / Cash FlowN/A Book Value$14.54 per share Price / Book1.32Miscellaneous Outstanding Shares27,450,000Free Float25,336,000Market Cap$528.69 million OptionableOptionable Beta0.93 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Derek J. Maetzold (Age 62)Founder, CEO, President & Director Comp: $1.45MMr. Frank Stokes (Age 53)CFO & Treasurer Comp: $849.36kMs. Kristen M. Oelschlager R.N. (Age 56)Chief Operating Officer Comp: $782.7kMr. Tobin W. Juvenal (Age 64)Chief Commercial Officer Comp: $782.7kCamilla ZuckeroVice President of Investor Relations & Corporate AffairsMs. Alice Bahner IzzoSenior Vice President of MarketingMr. Kevin DomanVice President of SalesMs. Keli GreenbergVP of Human Resources & Executive Director of Human ResourcesDr. Robert W. Cook Ph.D. (Age 52)Senior Vice President of Research & Development Dr. Matthew Goldberg M.D.Senior Vice President of MedicalMore ExecutivesKey CompetitorsFulgent GeneticsNASDAQ:FLGTCareDxNASDAQ:CDNASera PrognosticsNASDAQ:SERAGenetronNASDAQ:GTHBiodesixNASDAQ:BDSXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 5,123 shares on 4/18/2024Ownership: 0.040%Derek J MaetzoldSold 1,947 sharesTotal: $39,621.45 ($20.35/share)Daniel BradburySold 2,400 sharesTotal: $49,080.00 ($20.45/share)Daniel BradburySold 9,152 sharesTotal: $196,310.40 ($21.45/share)Derek J MaetzoldSold 2,368 sharesTotal: $51,385.60 ($21.70/share)View All Insider TransactionsView All Institutional Transactions CSTL Stock Analysis - Frequently Asked Questions Should I buy or sell Castle Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks. What is Castle Biosciences' stock price target for 2024? 3 analysts have issued 1 year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $37.00. On average, they predict the company's share price to reach $31.00 in the next year. This suggests a possible upside of 61.5% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts. How have CSTL shares performed in 2024? Castle Biosciences' stock was trading at $21.58 on January 1st, 2024. Since then, CSTL shares have decreased by 11.0% and is now trading at $19.20. View the best growth stocks for 2024 here. When is Castle Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CSTL earnings forecast. How can I listen to Castle Biosciences' earnings call? Castle Biosciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) announced its earnings results on Wednesday, February, 28th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.74. The firm earned $66.12 million during the quarter, compared to analyst estimates of $51.32 million. Castle Biosciences had a negative trailing twelve-month return on equity of 14.92% and a negative net margin of 26.15%. What ETF holds Castle Biosciences' stock? First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio. What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC). When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Castle Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Kristen M Oelschlager, Tiffany Olson and Tobin W Juvenal. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CSTL) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.